Dr Bushra Ateeq has made path breaking research on the resistance to androgen deprivation therapy, mainstay treatment for prostate cancer patients. She showed that antiandrogen drugs used for treatment of advanced stage prostate cancer patients are actually detrimental in the long-term, and Casein Kinase 1 inhibitors could be included as an adjuvant therapy for SPINK1-positive and neuroendocrine prostate cancer patients.